[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Karl Landsteiner University of Health Sciences\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":193},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,48,76,108,135,164],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100597252","prevention-of-desaturations-using-positive-airway-pressure-or-capnometry-during-ercp-100597252",false,"NCT07056075","Prevention of Desaturations Using Positive Airway Pressure or Capnometry During ERCP","A Randomized, Controlled, Unblinded Trial Evaluating the Impact of Positive Airway Pressure and Capnometry Compared to Standard Management on the Rate of Desaturations During Nurse-administered Sedation ERCP","PrePAP-ERCP","Inclusion Criteria:\n\n* undergoing an interventional (intent) ERCP procedure\n* 18-99 years\n* Male or female\n* Nurse-administered sedation\n\nExclusion Criteria:\n\n* History of allergic reaction to Propofol\n* Tracheostomy\n* Procedure requiring intubation, general anesthesia, or anesthesiologist backup (acute exacerbation of obstructive lung disease, acute congestive heart failure, supra-glottic or sub-glottic tumor, septic shock, e.g.) according to the endoscopist in charge\n* Pregnant patients","ALL","18 Years","99 Years",{"count":21,"type":22},288,"ESTIMATED","INTERVENTIONAL",[25],"NA","Although sedation during endoscopy is sufficiently safe, desaturations are among the most common side effects of endoscopic retrograde cholangiopancreatography (ERCP) procedures, occurring in approximately 20-30% of cases. Sedation during endoscopy increases the complication rate, and a significant proportion of severe and serious side effects are respiratory\u002Fairway-related. However, most patients require sedation to complete the procedure and achieve adequate outcomes during therapeutic ERCP. Therefore, improved measures to increase ERCP safety are needed. Since the demand for anesthesia in many centers already (far) exceeds current capacities, performing additional ERCPs under general anesthesia is not an option. Innovative ways to improve cardiorespiratory monitoring or respiratory management during ERCP could offer a solution without significantly increasing costs. Fortunately, dedicated devices for respiratory management and\u002For monitoring during endoscopy already exist, but their impact on improving patient safety has not yet been well studied. Therefore, the aim of this prospective, randomized, open-label, non-interventional study is to investigate the effects of non-invasive airway management and respiratory monitoring devices on desaturation rate during endoscopic retrograde cholangiopancreatography.\n\nFor this purpose, 288 adult patients (male and female, 18+ years) undergoing ERCP for medical reasons will be enrolled and randomized to one of three groups: (i) airway management using positive airway pressure (PAP group), (ii) additional monitoring using capnography (capnography group), and (iii) a control group with standard monitoring\u002Ftreatment (i.e., 2 L O2\u002Fmin via nasal cannula) (control group). Patients are monitored during the ERCP procedure according to medical standards (non-invasive blood oxygen saturation measurement = SpO2, regular non-invasive blood pressure measurement, pulse), and all desaturation events (defined as an SpO2 \\\u003C85% for any duration according to guidelines) are recorded and treated according to guideline recommendations (the studies do not specify any measures for the (non-)treatment of desaturations). After the procedure, patients are followed (passively) for 30 days (review of medical records) to record late complications. The main outcome parameter is the comparison of the desaturation rate in the PAP versus the control group.",[28,29,30],"Desaturation","Hypoxemia","ERCP",[30,32,33,34],"Sedation-related adverse events","desaturation","trial","RECRUITING","2026-03-21",{"date":38,"type":39},"2026-03-24","ACTUAL",{"date":41,"type":39},"2025-07-07",{"date":43,"type":22},"2026-12-30",{"name":45,"class":46},"Karl Landsteiner University of Health Sciences","OTHER",2,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},"100625479","partial-tumor-irradiation-and-immunotherapy-for-unresectable-lung-cancer-100625479","NCT07423169","Partial Tumor Irradiation and Immunotherapy for Unresectable Lung Cancer","Rechallenge Using Combined Partial Tumor Irradiation and Immune Checkpoint Inhibitor-based Immunotherapy for Unresectable Lung Adenocarcinoma: a Pilot Study","Inclusion Criteria:\n\n1. Written informed consent\n2. Biopsy proven unresectable lung adenocarcinoma\n3. Ineligibility for surgery and conventional curative (whole tumor) radiotherapy, and relapsed\u002Frefractory to any previous standard of care therapy including ICI\n4. Age ≥ 18 years,\n5. Female patients must either be of non-reproductive potential (i.e. post-menopausal by history: ≥60 years old and no menses for ≥1 year without an alternative medical cause; OR history of hysterectomy, OR history of bilateral tubal ligation, OR history of bilateral oophorectomy) OR women of fertile age must have adequate conception prevention measures and must have a negative serum pregnancy test upon study entry,\n6. Patient is willing and able to comply with the follow up including scheduled visits and examinations,\n7. Adequate immune blood profile (not being immunodepressed): Leucocyte count ≥4000, Neutrophils count ≥1000.\n8. PDL-1 ≥ 1%\n\nExclusion Criteria:\n\n1. Patients with resectable\u002Fcurable lung cancer\n2. Tumors suitable for the standard of care therapies including surgery or conventional curative (whole tumor) radio-chemotherapy\n3. Lung cancer histology other than adenocarcinoma\n4. Female patients who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth control\n5. Any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results, (1)\n6. Patients with uncontrolled seizures.\n7. Inadequate immune blood profile (being potentially immunodepressed): Leucocyte count \\\u003C4000, Neutrophils count \\\u003C1000.\n8. PDL-1 \\\u003C 1%",{"count":56,"type":22},10,[25],"The present study will explore a novel treatment strategy for unresectable lung adenocarcinoma combining a unique unconventional radiotherapy technique for high dose partial tumor irradiation (PTI) sparing the peritumoral immune microenvironment (PIM) with an immune checkpoint inhibitor (ICI)-based immunotherapy. The present study will focus on patients with larger, unresectable bulky lung tumors who previously failed standard of care therapy, or are unsuitable for conventional radio-chemotherapy due to tumor size and volume, and do not have any further therapeutic option left. This concept implies that a very high, ablative radiation dose (typically 20-25Gy per fraction) is delivered exclusively to the central bulky-tumor segment sparing at the same time surrounding PIM and therefore preserving its function.\n\nThe present study will explore the potential clinical advantages of the above described innovative treatment concept as a rechallenge treatment: following the disease progression during initiated first-line ICI-therapy, or following discontinuation of ICI-therapy, a same previously used agent (ICI) will be added the PTI to boost its immunologic anti-tumor effects. The treatment response will be measured by comparing the progression-free survival 1 (PFS-1) (ICI-therapy alone) and progression-free survival 2 (PFS-2) (combined rechallange PTI-ICI) rates.\n\nThe primary endpoint will be ∆PFS rate (PFS-2 vs PFS-1) assessed according to the modified iRECIST criteria. Secondary endpoints will include overall survival, toxicity, and exploration and validation of the anti-cancer immunity.\n\nOnce treatment is completed, follow up will be performed on a regular basis (at 6 and 12 weeks, and every 3 months later on) by CT, MRT or PET-CT imaging to allow for endpoints assessment, or at any time in case of suspected disease progression. Patients will also be followed clinically with history and physical examinations, vital signs, and laboratory examinations as indicated.",[60,61,62],"Lung Adenocarcinoma","Bulky Tumors","Unresectable Cancer",[64,65,66],"Partial Irradiation","Immunomodulation","Radio-Vaccine","2026-02-18",{"date":69,"type":39},"2026-02-20",{"date":71,"type":39},"2026-02-02",{"date":73,"type":22},"2028-02",{"name":45,"class":46},1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":87,"conditions":88,"keywords":93,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":75},"100611865","leadless-pacemaker-registry-outcomes-and-follow-up-from-the-university-hospital-of-st-plten-100611865","NCT07246135","Leadless Pacemaker Registry: Outcomes and Follow-up From the University Hospital of St. Pölten","Leadless Pacemaker Registry","LPR","Inclusion Criteria:\n\n* Patients undergoing implantation of a leadless pacemaker at the University Hospital of St. Pölten\n* Patients who previously received a leadless pacemaker between June 2015 and the start of the registry (retrospective inclusion).\n* Age ≥ 18 years.\n* Written informed consent provided by the patient.\n\nExclusion Criteria:\n\n* Patients who decline or are unable to provide informed consent.\n* Patients in whom a conventional transvenous pacemaker is implanted (i.e., not leadless).\n* Any condition that, in the opinion of the treating physician, precludes participation in the registry.",{"count":85,"type":22},700,"OBSERVATIONAL","The registry for leadless pacemakers will collect and annually analyze the data of all leadless pacemaker implantations at the University Hospital St. Pölten, including demographic information, indications, procedural details, acute, medium- and long-term complications during follow-up. Due to the partially novel nature of the signals (atrial mechanical sensing markers) and the lack of long-term experience to date, data on these aspects will also be collected and analyzed.\n\nThis is a single-center, prospective and retrospective registry that includes all patients receiving a leadless pacing device, as well as all patients who received a leadless pacing device between January 2021 and the start of the registry. All patients undergoing implantation of a leadless pacemaker will be invited to participate in the registry. For patients to be included retrospectively, participation in the registry will be offered at the time of their next routine follow-up visit.\n\nThe indication for leadless pacing will be determined by the physician responsible for the patient. Enrollment in the registry will in no case alter or influence the treatment the patient receives. Data collection will take place at the time of implantation and continuously during follow-up over the entire study period. Pacemaker-related data may be obtained either in person or via remote monitoring.",[89,90,91,92],"Pacemaker","Leadless Pacemaker","Cardiac Pacing, Artificial","Registries",[94,90,89,95,96,97,98,99],"Registry","Cardiac Pacing","Pacemaker Complication","Leadless Pacemaker Outcomes","Heart Conduction System Disease","Bradycardia","2025-11-17",{"date":102,"type":39},"2025-11-24",{"date":104,"type":39},"2015-06-18",{"date":106,"type":22},"2035-01",{"name":45,"class":46},{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":117,"conditions":118,"keywords":122,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":75},"100549328","hepatomir-cacld-study-100549328","NCT06432582","hepatomiR cACLD Study","Assessment of a hepatomiR Cut-off for Predicting Specific Hepatic Decompensation Events in Advanced Chronic Liver Disease","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Chronic liver disease (more than 6 months)\n* LSM ≥ 10 kPa\n* Outpatient at the Clinical Department of Internal Medicine II, University Hospital St. Pölten\n* Signed patient consent form\n\nExclusion Criteria:\n\n* Age older than 18 years\n* Pregnancy\n* Primary hepatic malignancy (hepatocellular carcinoma, cholangiocarcinoma) with portal invasion and\u002For extrahepatic spread",{"count":116,"type":22},156,"This study looks to gather data on hepatomiR, a CE-certified test already intended for gauging liver-related outcomes, in order to define a cut-off regarding specific decompensation events (ascites, variceal hemorrhage, hepatic encephalopathy) in chronic liver disease (CLD). Based on these data, it is aimed to advance the current understanding of factors driving decompensation, with potential repercussions for future risk management and therapy.",[119,120,121],"Chronic Liver Disease and Cirrhosis","Chronic Liver Disease","Portal Hypertension",[123,124,125,126],"hepatomiR","micro-RNA","hepatic decompensation","ACLD","2025-09-08",{"date":129,"type":39},"2025-09-09",{"date":131,"type":39},"2024-05-15",{"date":133,"type":22},"2026-06",{"name":45,"class":46},{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":142,"targetDuration":144,"studyType":86,"phases":4,"briefSummary":145,"conditions":146,"keywords":154,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":163,"locationsCount":75},"100453913","register-study-implementation-of-pharyngeal-electrostimulation-therapy-for-the-treatment-of-acute-neurogenic-dysphagia-100453913","NCT05190718","Register Study: Implementation of Pharyngeal Electrostimulation Therapy for the Treatment of Acute Neurogenic Dysphagia","R:IphEst","Inclusion Criteria:\n\n* Neurogenic dysphagia\n\n  * Ischaemic and haemorrhagic strokes\n  * Infra- as well as supra-tentorial\n  * Polyradiculitis\n  * Parkinson's disease\n  * Multiple sclerosis\n  * Dementia\n  * Traumatic brain injury\n  * Post Covid-19 pat.\n* patients over the age of 18.\n\nExclusion Criteria:\n\n* Contraindication to nasogastric tube,\n* Unstable cardiac or respiratory condition that does not allow the insertion of the Nasogastric tube\n* Pacemakers\n* Implanted defibrillators (ICD)\n* Pregnant\n* Breastfeeding women\n\n(Caution: interfering signals may be visible in ECGs, \\& EEGs with continuous recording).",{"count":143,"type":22},100,"90 Days","Neurogenic dysphagia occurs with disruption of neurological systems or processes involved in the execution of coordinated and safe swallowing. It is common in patients with neurological diseases, in particular in patients treated in Intensive Care Units (ICU) who are intubated (up to 62%) and \u002F or tracheotomised (up to 83%). Dysphagia is one of the most common and most dangerous symptoms of many neurological diseases. In addition, neurogenic dysphagia can have a significant impact on quality of life, medication efficacy, and malnutrition.\n\nDysphagia is currently treated conservatively on evidence-based exercises, individually adapted to each patient. In the recent years pharyngeal electrostimulation has been established and shown a positive impact on outcome. In fact, this type of therapy has not only become an addition to the existing therapy, but an important alternative for patients difficult to treat by other means.\n\nThe Phagenyx® is a medical device, which has lately been used more frequently in multiple hospitals for treatment of neurogenic dysphagia. For nearly two decades pharyngeal electrostimulation has been further developed and optimised. This therapy initiates changes in the swallowing motor cortex through neuroplasticity as well as local changes in peripheral sensory architecture associated with swallowing. Bath and colleagues (2020) recently reported the efficacy of pharyngeal electrostimulation (Phagenyx®) in various neurological conditions.\n\nAs a result, of current published studies, the use of pharyngeal electrostimulation probe, in selected patients, with neurological diseases with moderate to severe neurogenic dysphagia will be evaluated.\n\nThis trial will initially start as quality assurance project with the aim to extent it into a monocentric based register study.\n\nThe Investigators aim to validate the effectiveness of pharyngeal electrostimulation for the treatment of moderate to severe neurogenic dysphagia by systematically recording specific dysphagia-relevant parameters. At present, it is still uncertain to what extent patients with neurogenic dysphagia in the context of a non-acute neurological disease could benefit from this method.\n\nThe research questions:\n\nDoes the use of the pharyngeal electrostimulation probe have an influence on the outcome of dysphagia in patients with moderate to severe neurogenic dysphagia? How long after therapy, can the use of the pharyngeal electrostimulation probe lead to oral food intake and\u002For removal of a tracheal cannula?",[147,148,149,150,151,152,153],"Neurogenic Dysphagia","Traumatic Brain Injury","Stroke","Dysphagia","Long Covid-19","Intubation Complication","Polyradiculitis",[147,150,148,155,149,156,151],"Phagenyx","Pharyngeal electrical stimulation","2025-03-04",{"date":159,"type":39},"2025-03-07",{"date":161,"type":39},"2021-12-15",{"date":43,"type":22},{"name":45,"class":46},{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":170,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":172,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":174,"conditions":175,"keywords":180,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":75},"100442655","echocardiographic-predictors-of-atrial-fibrillation-100442655","NCT05044208","Echocardiographic Predictors of Atrial Fibrillation","Echocardiographic Predictors of Atrial Fibrillation in Patients With ESUS or TIA - Detected With 7-day ECG Monitor","EPAF-7","Inclusion Criteria:\n\nAge ≥ 18 years, written informed consent to participate in the study Clinical diagnosis of ischemic stroke or transient ischemic attack + brain imaging to rule out hemorrhagic stroke.\n\n1. Stroke: ESUS, defined as all of the following:\n\n   * Stroke detected by CT (computertomography) or MRI (magnetic resonance imaging) that is not lacunar. (Lacunar is defined as a subcortical (this includes pons and midbrain) infarct in the distribution of the small, penetrating cerebral arteries whose largest dimension is ≤1.5 cm on CT or ≤2.0 cm on MRI diffusion images\u002F\\\u003C1.5 cm on T2 weighted MR images. The following are not considered lacunes: multiple simultaneous small deep infarcts, lateral medullary infarcts, and cerebellar infarcts.)\n   * Absence of extracranial or intracranial atherosclerosis causing ≥50 percent luminal stenosis of the artery supplying the area of ischemia. Patients must undergo vascular imaging of the extracranial and intracranial vessels using either catheter angiography, CT angiogram (CTA), MR angiogram (MRA), or ultrasound, as considered appropriate by the treating physician and local principal investigator.\n   * No major-risk cardioembolic source of embolism, including intracardiac thrombus, mechanical prosthetic cardiac valve, atrial myxoma or other cardiac tumors, mitral stenosis, myocardial infarction within the last 4 weeks, left ventricular ejection fraction \\\u003C30 percent, valvular vegetations, or infective endocarditis).\n   * No other specific cause of stroke identified, such as arteritis, dissection, migraine, vasospasm, drug abuse, or hypercoagulability. Special testing, such as toxicological screens, serological testing for syphilis, and tests for hypercoagulability, will be performed at the discretion of the treating physician and local principal investigator, if needed.\n2. TIA: Patients fulfilling all above criteria and diagnostic work-up, except the detection of ischemic lesions by CT or MRI is optional and clinical symptoms last \\\u003C 1 hours.\n\nAll patients must undergo electrocardiogram, transthoracic or transesophageal echocardiography (TTE or TEE) and at least 24 hours of cardiac rhythm monitoring (Holter monitor or telemetry or equivalent).\n\nPatent foramen ovale is not an exclusion criterion. Planned or existing implantation of an implantable cardiac monitor or cardiac pacemaker is not an exclusion criterion.\n\nExclusion Criteria:\n\n* History of AF, AF on 12-lead ECG, or any AF of any duration during heart-rhythm monitoring prior to inclusion into the study\n* Technical problems or bad quality of the echocardiogram making it impossible to measure the main parameters for calculating the LaHAsPa-Score (sPA-TDI, LAVI)\n* Wearing time \\\u003C 1 week (combined recording time \\\u003C 168 hours) due to patient withdrawing from study, patch dissolving or technical defects\n* Life expectancy \\\u003C 1 month\n* Patients under custody or mentally not being able to give written informed consent",{"count":173,"type":22},200,"This prospective study aims to identify the diagnostic accuracy of echocardiographic predictors of atrial fibrillation in patients with ESUS (embolic stroke of undetermined source) or TIA (transient ischemic attack).",[176,177,178,179],"Atrial Fibrillation","Stroke, Ischemic","Embolic Stroke of Undetermined Source","TIA, Brain",[181,182,183,184],"Echocardiography","Total Atrial Conduction Time","Left Atrial Strain","Left Atrial Volume","2023-03-07",{"date":187,"type":39},"2023-03-08",{"date":189,"type":39},"2021-01-01",{"date":191,"type":22},"2026-11",{"name":45,"class":46},""]